Table 1.
Patient characteristics (n = 125)
| Characteristic | Median (range) or n (%) |
|---|---|
| Age (years) | 63 (54–72) |
| Histology | |
| IDC | 97 (76.6) |
| Non-IDC | 28 (23.4) |
| Time since occurrence of skin metastases (mo) | 32 (9–109) |
| Skin metastases (n = 239) | |
| No. per patient | 1 (1–3) |
| Size (mm) | 21 (15–45) |
| Location | |
| Chest | 222 (92.9) |
| Other site | 17 (7.1) |
| Skin condition | |
| Previous radiotherapy | 92 (38.5) |
| Lymphedema | 30 (12.6) |
| Ulceration | 64 (26.8) |
| Immunohistochemistry | |
| ER positive | 72 (57.6) |
| PgR positive | 72 (57.6) |
| HER2 overexpression | 35 (28.0) |
| Ki-67 < 14 % | 63 (50.4) |
| Surrogate subtypesa | |
| Luminal A-like | 23 (18.4) |
| Luminal B-like (HER2 negative) | 22 (17.6) |
| Luminal B-like (HER2 positive) | 18 (14.4) |
| Triple negative | 35 (28) |
| HER2 | 11 (8.8) |
| Previous treatmentsb | |
| Radiotherapy | 68 (54.4) |
| Chemotherapy | 92 (73.6) |
| Endocrine therapy | 71 (56.8) |
| Targeted therapy | 14 (11.2) |
| Surgery for skin metastases | 89 (71.2) |
IDC invasive ductal carcinoma, ER estrogen receptor, PR progesterone receptor
aAssessed on 113 patients, according to St. Gallen consensus11
bAny setting